Search

Displaying results 4221 - 4230 of 4590 in total
  1. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

  2. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

    Synonyms: K-CABProducts: K-CAB Tablet 50mg
  3. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.

  4. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A220143, A196128] In an unbiased screen for compounds capable of reducing cell death induced by infection with the influenza strain H5N1, ifenprodil was found to have a protective effect against H5N1-

  5. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. Experimental studies are still being investigated to determine all of the physiological effects...

  6. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  7. Drug

    Cefovecin

    go.drugbank.com/drugs/DB11505
    ExperimentalVet approved

    It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs.

  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.

  9. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is

  10. Drug

    Lysergic acid diethylamide

    go.drugbank.com/drugs/DB04829
    IllicitInvestigational

    Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence.